High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

Objectives Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in routine clinical practice. Methods Two ongoing prospective multicenter cohorts of...

Descripción completa

Detalles Bibliográficos
Autores: González-Serna Martín, Manuel Alejandro, Macías Sánchez, Juan, Corma Gómez, Anaïs, Tellez, Francisco, Cucurull, Josep, Real Navarrete, Luis Miguel, Granados, Rafael, Rivero Juárez, Antonio, Hernández Quero, José, Merino, Dolores, Palacios, Rosario, Ríos-Villegas, María José, Collado, Antonio, Pineda Vergara, Juan Antonio
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/156690
Acceso en línea:https://hdl.handle.net/11441/156690
https://doi.org/10.1016/j.jinf.2022.06.005
Access Level:acceso abierto
Palabra clave:Glecaprevir/pibrentasvir
HCV therapy
Drug use
Opiate agonist therapy
PWID
Descripción
Sumario:Objectives Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in routine clinical practice. Methods Two ongoing prospective multicenter cohorts of individuals starting G/P were analyzed. Overall SVR intention-to-treat (ITT), discontinuations due to adverse effects and dropouts were evaluated. Results in patients with active, past and without active drug use were compared. Results Overall, 644 individuals started G/P and have reached the date of SVR evaluation. Of them, 613 (95.2%) individuals achieved SVR. There were two (0.3%) relapses, one (0.2%) discontinuation due to side effects and 35 (5.4%) dropouts. SVR rates for patients with active drug use, past drug use and those who never used drugs were 85.4%(n/N = 70/82), 96.1%(n/N = 320/333) and 97.4%(n/N = 223/229) respectively (p < 0.001). After adjustment by sex, age, HCV genotype and opioid agonist therapy, active drug use was the only factor independently associated with SVR (ITT) [adjusted OR (95%confidence interval): 0.29(0.09–0.99),p = 0.048]. Conclusions Active drug use was independently associated with lower SVR rates to G/P, mainly due to voluntary dropout. G/P could be particularly beneficial in this scenario but specific strategies designed to increase the retention in care are needed.

Similares en LA Referencia